Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country.

Euroasian J Hepatogastroenterol · 2024 · PMC11714103 · PMID 39802845

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantp < 0.001actually significant

The median OS for ALBI grade I patients was 21 (95% CI: 11–54) months, and for ALBI grade II and III patients, it was 5 (95% CI: 4–9) months, with a highly significant difference among groups ( p < 0.001) ( Fig. 2 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.